First-Line Lenvatinib Plus Pembrolizumab or Everolimus versus Sunitinib for Advanced Renal Cell Carcinoma: A United States-Based Cost-Effectiveness Analysis
Open Access
- 25 November 2022
- journal article
- research article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 21 (3) , 417.e1-417.e10
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database ConsortiumClinical Genitourinary Cancer, 2015
- Economic Outcomes of Maintenance Gefitinib for Locally Advanced/Metastatic Non-Small-Cell Lung Cancer with Unknown EGFR Mutations: A Semi-Markov Model AnalysisPLOS ONE, 2014
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based studyThe Lancet Oncology, 2013
- Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level DataMedical Decision Making, 2013
- Comparing Local and Regional Variation in Health Care SpendingNew England Journal of Medicine, 2012
- Cost Effectiveness of Personalized Therapy for First-Line Treatment of Stage IV and Recurrent Incurable Adenocarcinoma of the LungJournal of Oncology Practice, 2012
- Economic Evaluation of Everolimus versus Sorafenib for the Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line SunitinibValue in Health, 2011
- Improved curve fits to summary survival data: application to economic evaluation of health technologiesBMC Medical Research Methodology, 2011
- Elicitation of health state utilities in metastatic renal cell carcinomaCurrent Medical Research and Opinion, 2010
- Cost-Effectiveness of Temsirolimus for First Line Treatment of Advanced Renal Cell CarcinomaValue in Health, 2010